Prediction of relapse in hyperthyroid Graves' disease.
Within a year of stopping a 6-month course of carbimazole treatment 41 of 65 patients (63%) with hyperthyroid Graves' disease had a recurrence of their hyperthyroidism. By combined analysis of the HLA-DRw3 status and the level of thyrotrophin-receptor antibody at the time of drug withdrawal relapse or remission could be predicted in 62 of the 65 patients.
D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000032:analysis; D002231:Carbimazole / Q000008:administration & dosage*; D005260:Female; D006111:Graves Disease / Q000188:drug therapy* / Q000276:immunology; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000276:immunology; D012008:Recurrence; D012075:Remission, Spontaneous; D013972:Thyrotropin / Q000276:immunology; D013997:Time Factors
D001323:Autoantibodies; D006680:HLA Antigens; D011956:Receptors, Cell Surface; D002231:Carbimazole; D013972:Thyrotropin